FDA Guidance Focuses on Clinical Trials for Acne Treatments

Drug Industry Daily
KEYWORDS FDA / Guidances
A A

Pharmaceutical firms developing treatments for chronic acne should design clinical studies with co-primary endpoints that evaluate both acne lesion counts and an investigator’s global assessment (IGA) scale of overall acne severity, according to a new FDA draft guidance.

To View This Article:

Login

Subscribe To Drug Industry Daily